Stichting Epilepsie Instellingen Nederland

Running trials

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Recruiting

  A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

  NCT05816382· Phase 2/3· Takeda· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy1 recruiting

Closed trials

• Completed

  A Study of TAK-861 for the Treatment of Narcolepsy Type 1

  NCT06470828· Phase 3· Takeda· Source

• Completed

  A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

  NCT06358950· Phase 2· Alkermes, Inc.· Source

• Completed

  Cortical Excitability and Treatment Response in People with Epilepsy

  NCT05551403· Stichting Epilepsie Instellingen Nederland· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Takeda· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

  NCT04940624· Phase 3· Takeda· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Narcolepsy21 works · 3 trials